StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report issued on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
NASDAQ NBRV opened at $0.00 on Friday. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. The firm has a market cap of $6,403.00, a P/E ratio of 0.00 and a beta of 1.53.
About Nabriva Therapeutics
See Also
- Five stocks we like better than Nabriva Therapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are Trending Stocks? Trending Stocks Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a support level?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.